Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN4336 Alone or With REGN5678 in Metastatic Castration-Resistant Prostate Cancer
NCT05125016Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Mar 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of REGN4336 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Regeneron Pharmaceuticals. Started Nov 2021; status: recruiting.
02
Drugs
REGN4336
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05125016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125016.